Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.40 |
| ▸ | TUBB | P07437 | 4/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6106129 | 0.83 | VNN1 (0.50) | RPS6KB1AURKAAURKBVNN1TUBB4A | |
| SCHEMBL6106240 | 0.82 | VNN1 (0.49) | RPS6KB1AURKAMAPTVNN1KDR | |
| SCHEMBL6104003 | 0.82 | CYP1A2 (0.49) | RPS6KB1AURKAVNN1KDRUSP1 | |
| SCHEMBL6105748 | 0.82 | VNN1 (0.46) | RPS6KB1AURKAAURKBVNN1KDR | |
| SCHEMBL6107998 | 0.82 | VNN1 (0.48) | RPS6KB1AURKAMAPTAURKBVNN1 | |
| SCHEMBL449066 | 0.81 | HDAC6 (0.45) | RPS6KB1AURKAAURKBPDE5AVNN1 | |
| SCHEMBL6106120 | 0.80 | PTK2 (0.47) | RPS6KB1AURKAAURKBVNN1PTK2 | |
| SCHEMBL6103869 | 0.80 | PTK2 (0.48) | RPS6KB1AURKAAURKBVNN1POLB | |
| SCHEMBL6104556 | 0.80 | PTK2 (0.48) | RPS6KB1AURKAAURKBVNN1PTK2 | |
| SCHEMBL6104170 | 0.77 | CDC7 (0.43) | RPS6KB1VNN1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | RPS6KB1 4382/4885AURKA 2147/4885MAPT 4232/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | RPS6KB1 3955/4885AURKA 3085/4885MAPT 4726/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | RPS6KB1 4382/4885AURKA 2147/4885MAPT 4232/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | RPS6KB1 3955/4885AURKA 3085/4885MAPT 4726/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | RPS6KB1 4195/4885AURKA 2856/4885MAPT 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.